{"id":"https://openalex.org/W2340276103","doi":"https://doi.org/10.1200/jco.2005.23.16_suppl.7062","title":"A phase I dose-escalating study of combination pemetrexed-based chemotherapy and concomitant radiotherapy for locally advanced or metastatic non-small cell lung or esophageal cancer","display_name":"A phase I dose-escalating study of combination pemetrexed-based chemotherapy and concomitant radiotherapy for locally advanced or metastatic non-small cell lung or esophageal cancer","publication_year":2005,"publication_date":"2005-06-01","ids":{"openalex":"https://openalex.org/W2340276103","doi":"https://doi.org/10.1200/jco.2005.23.16_suppl.7062","mag":"2340276103"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2005.23.16_suppl.7062","doi":"https://doi.org/10.1200/jco.2005.23.16_suppl.7062","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2005.23.16_suppl.7062","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5008467612","display_name":"Tanguy Y. Seiwert","orcid":"https://orcid.org/0000-0001-7919-8272","observed_orcids":["https://orcid.org/0000-0001-7919-8272"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]},{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"T. Y. Seiwert","raw_affiliation_strings":["Univ of Chicago, Chicago, IL; Eli Lilly & Co, Indianapolis, IN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Univ of Chicago, Chicago, IL; Eli Lilly & Co, Indianapolis, IN","institution_ids":["https://openalex.org/I168537998","https://openalex.org/I40347166"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052892126","display_name":"Phillip P. Connell","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]},{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"P. P. Connell","raw_affiliation_strings":["Univ of Chicago, Chicago, IL; Eli Lilly & Co, Indianapolis, IN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Univ of Chicago, Chicago, IL; Eli Lilly & Co, Indianapolis, IN","institution_ids":["https://openalex.org/I168537998","https://openalex.org/I40347166"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063976463","display_name":"Ann M. Mauer","orcid":"https://orcid.org/0000-0002-3975-0998","observed_orcids":["https://orcid.org/0000-0002-3975-0998"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]},{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"A. M. Mauer","raw_affiliation_strings":["Univ of Chicago, Chicago, IL; Eli Lilly & Co, Indianapolis, IN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Univ of Chicago, Chicago, IL; Eli Lilly & Co, Indianapolis, IN","institution_ids":["https://openalex.org/I168537998","https://openalex.org/I40347166"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111457658","display_name":"P. C. Hoffman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]},{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"P. C. Hoffman","raw_affiliation_strings":["Univ of Chicago, Chicago, IL; Eli Lilly & Co, Indianapolis, IN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Univ of Chicago, Chicago, IL; Eli Lilly & Co, Indianapolis, IN","institution_ids":["https://openalex.org/I168537998","https://openalex.org/I40347166"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111387863","display_name":"Christopher George","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]},{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"C. M. George","raw_affiliation_strings":["Univ of Chicago, Chicago, IL; Eli Lilly & Co, Indianapolis, IN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Univ of Chicago, Chicago, IL; Eli Lilly & Co, Indianapolis, IN","institution_ids":["https://openalex.org/I168537998","https://openalex.org/I40347166"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012655110","display_name":"Livia L. Szeto","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]},{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"L. Szeto","raw_affiliation_strings":["Univ of Chicago, Chicago, IL; Eli Lilly & Co, Indianapolis, IN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Univ of Chicago, Chicago, IL; Eli Lilly & Co, Indianapolis, IN","institution_ids":["https://openalex.org/I168537998","https://openalex.org/I40347166"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016064449","display_name":"Coleman K. Obasaju","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]},{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"C. Obasaju","raw_affiliation_strings":["Univ of Chicago, Chicago, IL; Eli Lilly & Co, Indianapolis, IN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Univ of Chicago, Chicago, IL; Eli Lilly & Co, Indianapolis, IN","institution_ids":["https://openalex.org/I168537998","https://openalex.org/I40347166"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108207086","display_name":"D. J. Haraf","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]},{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"D. J. Haraf","raw_affiliation_strings":["Univ of Chicago, Chicago, IL; Eli Lilly & Co, Indianapolis, IN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Univ of Chicago, Chicago, IL; Eli Lilly & Co, Indianapolis, IN","institution_ids":["https://openalex.org/I168537998","https://openalex.org/I40347166"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003826371","display_name":"Ravi Salgia","orcid":"https://orcid.org/0000-0001-9643-7626","observed_orcids":["https://orcid.org/0000-0001-9643-7626"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]},{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"R. Salgia","raw_affiliation_strings":["Univ of Chicago, Chicago, IL; Eli Lilly & Co, Indianapolis, IN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Univ of Chicago, Chicago, IL; Eli Lilly & Co, Indianapolis, IN","institution_ids":["https://openalex.org/I168537998","https://openalex.org/I40347166"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5063904421","display_name":"Everett E. Vokes","orcid":"https://orcid.org/0000-0002-8645-8068","observed_orcids":["https://orcid.org/0000-0002-8645-8068"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]},{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"E. E. Vokes","raw_affiliation_strings":["Univ of Chicago, Chicago, IL; Eli Lilly & Co, Indianapolis, IN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Univ of Chicago, Chicago, IL; Eli Lilly & Co, Indianapolis, IN","institution_ids":["https://openalex.org/I168537998","https://openalex.org/I40347166"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":11,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"23","issue":"16_suppl","first_page":"7062","last_page":"7062"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10202","display_name":"Lung Cancer Diagnosis and Treatment","score":0.9833999872207642,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10202","display_name":"Lung Cancer Diagnosis and Treatment","score":0.9833999872207642,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.00930000003427267,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10307","display_name":"Head and Neck Cancer Studies","score":0.0010999999940395355,"subfield":{"id":"https://openalex.org/subfields/2733","display_name":"Otorhinolaryngology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pemetrexed","display_name":"pemetrexed","score":0.9959999918937683},{"id":"https://openalex.org/keywords/carboplatin","display_name":"carboplatin","score":0.7929999828338623},{"id":"https://openalex.org/keywords/chemoradiotherapy","display_name":"chemoradiotherapy","score":0.9390000104904175},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.8939999938011169},{"id":"https://openalex.org/keywords/esophageal-cancer","display_name":"esophageal cancer","score":1.0},{"id":"https://openalex.org/keywords/locally-advanced-cancer","display_name":"locally advanced cancer","score":0.8159999847412109},{"id":"https://openalex.org/keywords/metastatic-cancer","display_name":"metastatic cancer","score":0.9679999947547913},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.8870000243186951},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.7009999752044678},{"id":"https://openalex.org/keywords/esophagitis","display_name":"esophagitis","score":0.8859999775886536},{"id":"https://openalex.org/keywords/pulmonary-embolism","display_name":"pulmonary embolism","score":0.8569999933242798},{"id":"https://openalex.org/keywords/leukopenia","display_name":"leukopenia","score":0.8830000162124634},{"id":"https://openalex.org/keywords/combination-chemotherapy","display_name":"combination chemotherapy","score":0.6019999980926514},{"id":"https://openalex.org/keywords/radiotherapy-schedule","display_name":"radiotherapy scheduling","score":0.3400000035762787},{"id":"https://openalex.org/keywords/antifolate-drugs","display_name":"antifolate","score":0.48899999260902405},{"id":"https://openalex.org/keywords/second-line-treatment","display_name":"second-line therapy","score":0.5979999899864197},{"id":"https://openalex.org/keywords/treatment-related-toxicity","display_name":"treatment toxicity","score":0.4519999921321869},{"id":"https://openalex.org/keywords/overall-response-rate","display_name":"overall response rate","score":0.6579999923706055},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.6190000176429749}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9421614408493042},{"id":"https://openalex.org/C2777240266","wikidata":"https://www.wikidata.org/wiki/Q415220","display_name":"Pemetrexed","level":4,"score":0.6721133589744568},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6074985265731812},{"id":"https://openalex.org/C2779384505","wikidata":"https://www.wikidata.org/wiki/Q17007513","display_name":"Concomitant","level":2,"score":0.5878864526748657},{"id":"https://openalex.org/C2780873365","wikidata":"https://www.wikidata.org/wiki/Q496812","display_name":"Leukopenia","level":3,"score":0.5785044431686401},{"id":"https://openalex.org/C2781451048","wikidata":"https://www.wikidata.org/wiki/Q415588","display_name":"Carboplatin","level":4,"score":0.5390588045120239},{"id":"https://openalex.org/C2778424827","wikidata":"https://www.wikidata.org/wiki/Q5090613","display_name":"Chemoradiotherapy","level":3,"score":0.507009744644165},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.4905211329460144},{"id":"https://openalex.org/C2776907518","wikidata":"https://www.wikidata.org/wiki/Q1734165","display_name":"Performance status","level":3,"score":0.4782542288303375},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.46776100993156433},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.4667420983314514},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.4660187065601349},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.4611426293849945},{"id":"https://openalex.org/C2778850193","wikidata":"https://www.wikidata.org/wiki/Q3775974","display_name":"Febrile neutropenia","level":4,"score":0.4433198571205139},{"id":"https://openalex.org/C509974204","wikidata":"https://www.wikidata.org/wiki/Q180507","display_name":"Radiation therapy","level":2,"score":0.44135743379592896},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.4268091320991516},{"id":"https://openalex.org/C2779742542","wikidata":"https://www.wikidata.org/wiki/Q372701","display_name":"Esophageal cancer","level":3,"score":0.4256570041179657},{"id":"https://openalex.org/C2778496288","wikidata":"https://www.wikidata.org/wiki/Q6931269","display_name":"Mucositis","level":3,"score":0.4249208867549896},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.321174681186676},{"id":"https://openalex.org/C2778239845","wikidata":"https://www.wikidata.org/wiki/Q412415","display_name":"Cisplatin","level":3,"score":0.22332528233528137}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2005.23.16_suppl.7062","doi":"https://doi.org/10.1200/jco.2005.23.16_suppl.7062","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2005.23.16_suppl.7062","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2162225583","https://openalex.org/W1993712280","https://openalex.org/W2049286103","https://openalex.org/W1989083178","https://openalex.org/W2080373386","https://openalex.org/W2281489950","https://openalex.org/W1787077806","https://openalex.org/W2019626224","https://openalex.org/W2589711989","https://openalex.org/W2248240945"],"abstract_inverted_index":{"7062":[0],"Background:":[1],"Pemetrexed":[2],"(pem,":[3],"Alimta)":[4],"is":[5,25,284,333],"a":[6,34,78,345],"multitargeted":[7],"antifolate":[8],"approved":[9],"for":[10,37,92,254,267,327],"second-line":[11],"treatment":[12],"of":[13,30,54,191,314,337],"metastatic":[14,66,136],"non-small":[15],"cell":[16],"lung":[17],"cancer":[18,73],"(NSCLC).":[19],"Treatment":[20],"failure":[21],"with":[22,62,83,101,318,330],"chemoradiotherapy":[23],"(CRT)":[24],"frequently":[26],"due":[27],"to":[28,46],"development":[29],"distant":[31],"metastasis":[32],"suggesting":[33],"potential":[35],"need":[36],"more":[38],"effective":[39],"systemic":[40],"therapy.":[41,192],"The":[42,312],"primary":[43],"objective":[44],"was":[45,97,110,143,178,220],"determine":[47],"whether":[48],"pem":[49,98,111],"based":[50],"CRT":[51],"allows":[52,335],"administration":[53,336],"systemically":[55,338],"active":[56,339],"chemotherapy":[57,84],"doses.":[58],"Methods:":[59],"Patients":[60],"(pts)":[61],"locally":[63,133],"advanced":[64],"or":[65,71,352,355],"(dominant":[67],"local":[68],"symptoms)":[69],"NSCLC":[70,208],"esophageal":[72,165],"(ca)":[74],"were":[75,138,170,196,213,244,257],"enrolled":[76,159,206],"in":[77,344],"phase":[79,346],"I":[80],"dose-escalating":[81],"study":[82],"delivered":[85],"on":[86],"day":[87,322],"1,":[88],"every":[89,324],"21":[90,325],"days":[91,326],"2":[93,109,153,205,328],"cycles.":[94],"Schedule":[95,108,157,204,255,268],"1":[96,148,158,256,323],"(200\u2013600":[99],"mg/m2)":[100,118,317],"concurrent":[102,331],"radiotherapy":[103,332],"(RT)":[104],"40\u201366Gy":[105],"(2":[106],"Gy/d).":[107],"fixed":[112],"at":[113,188,222,234],"recommended":[114],"single-agent":[115],"dose":[116,168,211],"(500":[117,316],"and":[119,152,201,249,264,280,341],"escalating":[120],"carboplatin":[121,319],"doses":[122],"(AUC":[123,320],"4\u20136)":[124],"+":[125,225,237],"concomitant":[126],"RT":[127],"(40\u201366Gy).":[128],"Results:":[129],"30":[130],"pts":[131,161,270,287,301],"(18":[132],"advanced,":[134],"12":[135,207],"disease)":[137],"enrolled.":[139],"ECOG":[140],"performance":[141],"status":[142],"0":[144],"(8":[145,293],"pts,":[146,150],"26.7%),":[147],"(21":[149],"70.0%),":[151],"(1":[154],"pt,":[155],"3.3%).":[156],"18":[160],"(15":[162],"NSCLC,":[163],"3":[164,194,242,286],"ca);":[166],"all":[167,210],"levels":[169,212],"tolerable.":[171],"One":[172,180,215,228],"DLT":[173,216],"(Grade":[174],"[Gr]":[175],"4":[176,184,218,232],"esophagitis)":[177],"reported.":[179],"pt":[181,229],"developed":[182],"Gr":[183,193,231,289],"pulmonary":[185],"embolism":[186],"(PE)":[187],"the":[189],"end":[190],"toxicities":[195,243],"leukopenia":[197,233,245],"(n=3),":[198,246],"dysphagia":[199],"(1),":[200,248,273,279],"dehydration":[202,247],"(1).":[203,251],"pts;":[209],"tolerated.":[214],"(Gr":[217],"PE)":[219],"reported":[221],"500":[223,235],"mg/m2":[224,236],"AUC":[226,238],"6.":[227],"had":[230,271,288],"5.":[239],"Treatment-related":[240],"grade":[241],"fatigue":[250],"Overall":[252],"responses":[253,307],"PR":[258,274],"(n=5),":[259],"SD":[260,276],"(5),":[261],"PD":[262,278],"(6),":[263],"unknown":[265,281],"(2);":[266],"2,":[269],"CR":[272],"(3),":[275],"(4),":[277],"(3).":[282],"Study":[283],"on-going.":[285],"1/2":[290],"radiation":[291],"pneumonitis":[292],"d":[294],"-":[295],"8":[296],"w)":[297],"after":[298],"RT.":[299],"Several":[300],"underwent":[302],"curative":[303],"intent":[304],"surgery.":[305],"In-field":[306],"are":[308],"being":[309],"assessed.":[310],"Conclusions:":[311],"combination":[313],"pemetrexed":[315],"6)":[321],"cycles":[329],"feasible,":[334],"doses,":[340],"warrants":[342],"examination":[343],"II":[347],"trial.":[348],"Author":[349],"Disclosure":[350],"Employment":[351],"Leadership":[353],"Consultant":[354],"Advisory":[356],"Role":[357],"Stock":[358],"Ownership":[359],"Honoraria":[360],"Research":[361],"Funding":[362],"Expert":[363],"Testimony":[364],"Other":[365],"Remuneration":[366],"Eli":[367,369,371,373],"Lilly":[368,370,372,374]},"counts_by_year":[],"updated_date":"2026-10-01T08:54:57.152042","created_date":"2016-06-24T00:00:00"}